Preclinical CRO Invivotek is a global pre-clinical CRO specializing in small animal studies for drug discovery and early optimization, presenting a clear target for pharma and biotech clients seeking cost-effective, rapid in vivo testing and mechanism of action insights.

Therapeutic Scope With capabilities in Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular disease models, there are multiple cross-therapeutic niches to pursue cross-selling with clients developing assets in these areas.

Established Track Founded around 2012–2013 and operating as a GD3 company, Invivotek has longevity in the space, offering continuity and reliability which can be leveraged in outreach to programs nearing preclinical milestones.

Facility & Data State-of-the-art animal facility and integration of biochemical, molecular biology techniques, and primary cell assays enable comprehensive in vivo testing and biomarker exploration, appealing to teams needing robust data packages for regulatory readiness.

Growth Signals Revenue in the low-to-mid single-digit millions suggests a growth trajectory with potential for expanded project portfolio; outreach can position Invivotek for multi-program engagements and longer-term partnerships as clients scale.